Skip to content

Effect of S. boulardii (Probiotic) in treatment of childhood diarrhoea.

A double blind, multicenter, randomized, parallel group, comparative post marketing surveillance study to evaluate the efficacy and safety of S. boulardii (strain CNCM I-3799) ("LesunBerry") plus standard treatment (containing ORS and Zinc) in comparison with standard treatment alone in acute childhood diarrhoea.

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/07/009101
Enrollment
100
Registered
2017-07-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Acute Childhood Diarrhoea Health Condition 2: B962- Escherichia coli [E. coli ] as thecause of diseases classified elsewhere

Interventions

Intervention1: S. boulardii plus ORS and Zinc: S. boulardii (strain CNCM I-3799) ("LesunBerry") plus standard treatment containing ORS and Zinc Control Intervention1: ORS, Zinc and Maltodextrin: Stand

Sponsors

Investigator initiated trial
Lead Sponsor
Sundyota Numandis Pharmaceuticals Pvt Ltd
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: (1) Male and,or female children of age 3 months to 36 months (both inclusive) with acute diarrhoea. (2) Child having three or more loose stools in last 24 hrs. (3) Subjects parent(s) or legal guardian are willing to provide informed consent form and also willing to comply with all the study requirements.

Exclusion criteria

Exclusion criteria: -Dysentery (presence of visible blood in stools) -Clinical evidence of coexisting any acute systemic illness (for e.g. meningitis, sepsis, pneumonia) -Clinical evidence of chronic disease (for e.g. chronic liver disease, chronic renal disease, nephrotic syndrome) -Known case of chronic gastrointestinal disease like celiac disease or inflammatory bowel disease -Use of probiotics in previous week -Use of antibiotics or an other anti-diarrhoeal medication for the current episode of diarrhoea in previous week. -Invasive diarrhoea -Clinical evidence of severe malnutrition based on weight-for-Length less than 3 SD of WHO Reference Card -Severe dehydration (shock with diminished consciousness, lack of urine output, cool, moist extremities, a rapid and feeble pulse, low or undetectable blood pressure and pale skin) -Participation in any other clinical study during last 30 days -Children with any condition which in the opinion of the investigator makes the subject unsuitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Time of recovery from diarrhoea, (Duration of Diarrhoea based on consistency of stool (3 consecutive semi solid stool formed) or no stool in last 12 hr considered as recovery from diarrhoea.)Timepoint: 05 days

Secondary

MeasureTime frame
(1) Frequency of stool (2) Frequency of vomiting (3) Total ORS consumption (4) Date and time of first semi solid stool (5) Time of first rehydration (6) Consistency of stools (7) Number of relapses (8) Duration of relapses episodes Timepoint: 65 days

Countries

India

Contacts

Public ContactDr Milan Satia

Hitarth Children Hospital and Neonatal Care Unit

ppshah68@gmail.com079-26750272

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026